BioCentury | Sep 15, 2020
Deals

Buoyed by Phase III data, Marinus aims for first NDA in a rare seizure disorder

...indication. Both readouts led to sharp declines in Marinus’ share price (see “Marinus Plummets After PPD...
BioCentury | Aug 20, 2020
Finance

Science 37, Castor raise funds as decentralized trials gain traction

...in a series D1 round led by existing investors Lux Capital, Redmile Group and PPD Inc. (NASDAQ:PPD...
BioCentury | Jun 17, 2020
Finance

Royalty’s $1.7B IPO latest sign of a biopharma market on a roll

...$1.9 billion offering by contract researcher PPD Inc., which had a postmoney valuation of $9 billion (NASDAQ:PPD...
BioCentury | Jun 6, 2020
Finance

Daily Chart: NASDAQ’s dazzling debuts

...Inc. Lyra Therapeutics Inc. ORIC Pharmaceuticals Inc. Keros Therapeutics Inc. Zentalis Pharmaceuticals Inc. Imara Inc. Passage Bio Inc. Revolution Medicines Inc. Beam Therapeutics Inc. PPD Inc. Schroedinger...
BioCentury | May 5, 2020
Finance

May 4 Quick Takes: Following Lyra’s success, Ayala readies for NASDAQ IPO; plus Medable and Hyloris

...raised to more than $45 million. GSR Ventures led the round with participation from PPD Inc. (NASDAQ:PPD...
BioCentury | Apr 4, 2020
Finance

Steady as venBio goes

...biopharmas and CROs. Amgen Inc. (NASDAQ:AMGN) and Baxalta were LPs in Fund I, along with PPD...
BioCentury | Feb 14, 2020
Finance

You say you want a Revolution? Oncology company is latest to post big gain after IPO

...second largest of the bunch, trailing only the $1.9 billion offering by contract researcher PPD Inc. (NASDAQ:PPD...
...amid worries about U.S. trade with China and the COVID-19 (2019-nCoV) coronavirus. The rest, including PPD...
BioCentury | Feb 6, 2020
Finance

Schrödinger, Beam are latest to post gains after pricing larger-than-expected IPOs

...PPD Inc. (NASDAQ:PPD), which raised $1.6 billion via the sale of 60 million shares at $27. PPD...
BioCentury | Oct 5, 2019
Finance

Seeking bright spots in 4Q19 amid continued underperformance

...in March. SAGE-217 also is in development for the indication (see “Sage Broadens Spotlight on PPD”...
BioCentury | Jun 26, 2019
Company News

June 25 Company Quick Takes: Conatus restructuring; plus Almirall-Dermira, Acer, Glenmark and more

...approval. Shionogi will receive an undisclosed upfront payment and is eligible for sales milestones. Immvira, PPD...
Items per page:
1 - 10 of 281
BioCentury | Sep 15, 2020
Deals

Buoyed by Phase III data, Marinus aims for first NDA in a rare seizure disorder

...indication. Both readouts led to sharp declines in Marinus’ share price (see “Marinus Plummets After PPD...
BioCentury | Aug 20, 2020
Finance

Science 37, Castor raise funds as decentralized trials gain traction

...in a series D1 round led by existing investors Lux Capital, Redmile Group and PPD Inc. (NASDAQ:PPD...
BioCentury | Jun 17, 2020
Finance

Royalty’s $1.7B IPO latest sign of a biopharma market on a roll

...$1.9 billion offering by contract researcher PPD Inc., which had a postmoney valuation of $9 billion (NASDAQ:PPD...
BioCentury | Jun 6, 2020
Finance

Daily Chart: NASDAQ’s dazzling debuts

...Inc. Lyra Therapeutics Inc. ORIC Pharmaceuticals Inc. Keros Therapeutics Inc. Zentalis Pharmaceuticals Inc. Imara Inc. Passage Bio Inc. Revolution Medicines Inc. Beam Therapeutics Inc. PPD Inc. Schroedinger...
BioCentury | May 5, 2020
Finance

May 4 Quick Takes: Following Lyra’s success, Ayala readies for NASDAQ IPO; plus Medable and Hyloris

...raised to more than $45 million. GSR Ventures led the round with participation from PPD Inc. (NASDAQ:PPD...
BioCentury | Apr 4, 2020
Finance

Steady as venBio goes

...biopharmas and CROs. Amgen Inc. (NASDAQ:AMGN) and Baxalta were LPs in Fund I, along with PPD...
BioCentury | Feb 14, 2020
Finance

You say you want a Revolution? Oncology company is latest to post big gain after IPO

...second largest of the bunch, trailing only the $1.9 billion offering by contract researcher PPD Inc. (NASDAQ:PPD...
...amid worries about U.S. trade with China and the COVID-19 (2019-nCoV) coronavirus. The rest, including PPD...
BioCentury | Feb 6, 2020
Finance

Schrödinger, Beam are latest to post gains after pricing larger-than-expected IPOs

...PPD Inc. (NASDAQ:PPD), which raised $1.6 billion via the sale of 60 million shares at $27. PPD...
BioCentury | Oct 5, 2019
Finance

Seeking bright spots in 4Q19 amid continued underperformance

...in March. SAGE-217 also is in development for the indication (see “Sage Broadens Spotlight on PPD”...
BioCentury | Jun 26, 2019
Company News

June 25 Company Quick Takes: Conatus restructuring; plus Almirall-Dermira, Acer, Glenmark and more

...approval. Shionogi will receive an undisclosed upfront payment and is eligible for sales milestones. Immvira, PPD...
Items per page:
1 - 10 of 281